Linaclotide for Irritable Bowel Syndrome With Constipation: A 26-Week, Randomized, Double-blind, Placebo-Controlled Trial to Evaluate Efficacy and Safety

医学 安慰剂 便秘 肠易激综合征 临床终点 内科学 不利影响 腹痛 胃肠病学 排便 随机对照试验 病理 替代医学
作者
William D. Chey,Anthony Lembo,Bernard J. Lavins,Steven J. Shiff,Allen W. Mangel,Mark G. Currie,James E. MacDougall,Xinwei D. Jia,James Shao,Donald A. Fitch,Mollie Baird,Harvey Schneier,Jeffrey M. Johnston
出处
期刊:The American Journal of Gastroenterology [Lippincott Williams & Wilkins]
卷期号:107 (11): 1702-1712 被引量:408
标识
DOI:10.1038/ajg.2012.254
摘要

OBJECTIVES: Linaclotide is a minimally absorbed peptide guanylate cyclase-C agonist. The objective of this trial was to determine the efficacy and safety of linaclotide treatment in patients with irritable bowel syndrome with constipation (IBS-C) over 26 weeks. METHODS: This phase 3, double-blind, parallel-group, placebo-controlled trial randomized IBS-C patients to placebo or 290 μg of oral linaclotide once daily for a 26-week treatment period. The primary and the secondary efficacy assessments were evaluated over the first 12 weeks of treatment. Primary end points included the Food and Drug Administration's (FDA's) end point for IBS-C (responder: a patient who reported (i) improvement of ≥30% from baseline in average daily worst abdominal pain score and (ii) increase of ≥1 complete spontaneous bowel movement (CSBM) from baseline, both in the same week for ≥6/12 weeks) and three other primary end points, based on improvements in abdominal pain and CSBMs for 9/12 weeks. Adverse events (AEs) were monitored. RESULTS: In all, 804 patients (mean age=44 years, female=90%, white=78%) were evaluated; 33.7% of linaclotide-treated patients were FDA end point responders, vs. 13.9% of placebo-treated patients (P<0.0001) (number needed to treat=5.1, 95% confidence interval (CI): 3.9, 7.1). The pain responder criterion of the FDA end point was met by 48.9% of linaclotide-treated patients vs. 34.5% of placebo-treated patients (number needed to treat=7.0, 95% CI: 4.7, 13.1), and the CSBM responder criterion was met by 47.6% of linaclotide-treated patients, vs. 22.6% of placebo patients (number needed to treat=4.0, 95% CI: 3.2, 5.4). Remaining primary end points (P<0.0001) and all secondary end points (P<0.001), including abdominal pain, abdominal bloating, and bowel symptoms (SBM and CSBM rates, Bristol Stool Form Scale (BSFS) score, and straining), were also statistically significantly improved with linaclotide vs. placebo. Statistically significant differences from placebo were observed for responder and continuous end points over 26 weeks of treatment. AE incidence was similar between treatment groups, except for diarrhea, which caused discontinuation in 4.5% of linaclotide patients vs. 0.2% of placebo patients. CONCLUSIONS: Linaclotide 290 μg once daily significantly improved abdominal and bowel symptoms associated with IBS-C over 26 weeks of treatment.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
不二臣发布了新的文献求助10
刚刚
可爱的函函应助kkk采纳,获得10
刚刚
斯文败类应助偷乐采纳,获得10
刚刚
Ava应助mariawang采纳,获得10
1秒前
girl发布了新的文献求助10
1秒前
orixero应助szl采纳,获得10
1秒前
自然初露关注了科研通微信公众号
2秒前
yu完成签到 ,获得积分10
2秒前
KingXing完成签到,获得积分10
3秒前
粗犷的灵松完成签到 ,获得积分10
3秒前
yyyyy关注了科研通微信公众号
5秒前
小姚发布了新的文献求助10
5秒前
wjw完成签到,获得积分10
6秒前
6秒前
毛小驴完成签到,获得积分10
7秒前
谢俏艳完成签到,获得积分10
7秒前
lm发布了新的文献求助10
7秒前
7秒前
7秒前
852应助咕噜咕噜咕嘟咕嘟采纳,获得10
8秒前
8秒前
小哥门完成签到,获得积分10
9秒前
Puan发布了新的文献求助10
9秒前
9秒前
sylnd126发布了新的文献求助10
10秒前
11秒前
峥2发布了新的文献求助10
11秒前
11秒前
吵吵robot发布了新的文献求助10
11秒前
12秒前
Nami发布了新的文献求助10
12秒前
吴丹完成签到,获得积分10
14秒前
14秒前
开放雪碧完成签到,获得积分10
14秒前
白日梦发布了新的文献求助10
15秒前
15秒前
15秒前
szl发布了新的文献求助10
16秒前
16秒前
故晨完成签到 ,获得积分20
16秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3988786
求助须知:如何正确求助?哪些是违规求助? 3531116
关于积分的说明 11252493
捐赠科研通 3269766
什么是DOI,文献DOI怎么找? 1804771
邀请新用户注册赠送积分活动 881870
科研通“疑难数据库(出版商)”最低求助积分说明 809021